|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
ContraFect Corporation
| | | Phone: | (914) 207-2300 | Year Established: | 2008 | Ticker: | CM | Exchange: | NASDAQ | Main Contact: | Steven C. Gilman, Ph.D., CEO | | Other Contacts: | Josh Muntner, Senior VP, Business Development Paul Boni, Head of Investor Development and Strategy Natalie Bogdanos, General Counsel Michael Messinger, Senior VP, Finance Nancy Dong, VP, Controller Daniel Couto, Senior VP, VP, Manufacturing &
Facilities Operations Cara Cassino, M.D., CMO & Executive VP, R&D Lisa Ricciardi, COO
| | Company Description | ContraFect Corp. is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). | |
|
|
|
|
|